During this week's Strawman Meeting, we discussed valuations and taking a long term view as an edge in long term investing.
And, lo and behold, once again I am confronted with the worst investing decision in my life - that of doing some "analysis" on $PME in mid-2023 and concluding that at $70, it was too expensive.
And so, today it announces another monster contract ($300m for 10 years) and to stop myself feeling terrible, I've done a quick update. By the way, on that news the SP jumps $2bn! (As an analyst, when I'm feeling glum I do some analysis - it makes me feel better!)
So the structure of this analysis is as follows:
1) Quick DCF
2) Quick market analysis
3) Conclusion and discussion
1) Quick DCF
So, having looked at the accounts over the last 3-4 years, i've decided to run out a DCF for 20 years. It's pretty easy to model.
First 10 years, revenue CAGR 27%; Opex CAGR 20%
Next 10 years, revenue CAGR 15%; Opex CAGR 10%
Common assumptions:
- Ongoing capex at 5% of revenue (assuming they both update and extend the platform to take over more and more of the total available market of medical imaging software)
- Depreciate 34% of relevant LT assets pa (PPE, Intangibles, Leases)
- SOI growth at 0.15% p.a.
- Tax: 30%
- Cashflow growth beyond the explicit period 5% (note: you usually don't run more than 4%)
- WACC = 9%
- 100% equity funding (no debt) + a sensitivity with LT Debt:EBITDA = 0.5
Valuation $200/share
Of course, you can bump this up a bit if you add a little gearing to the balance sheet. If I add 50% of EBITDA as long term debt, I then get:
Valuation $218/share
As ever, you can get all sorts of valuations by tweaking the parameters, and I have omitted a few things (like deferred taxes etc. and adjusting the WACC in the leverage case). Playing with this model, I can get valuations down as low as $160 and up north of $230,but that's not the point of this thread. That comes next.
2) The Market
I'm reasonably confident that the global market for medical imaging software can be estimated to be in the ball park of A$5.6bn (fairly wide range of sources around this, but it's in the ball park).
Now $PME is not playing in this total market, but for the sake of this analysis (just like with $WTC), let's assume that over time it expands from its current focus to dominate the wider market.
So, today its market share is only 7%. Lot's of running room.
We know this market is growing at 7-8% per annum, and if I assume that for the next decade it grows at 8% pa, and thereafter at a more modest but still healthy 5%pa, then in 2045 the global market has become $18bn.
In 2045, with my DCF assumptions, $PME's market share has become 46%.
Now that would be a truly dominant market share when you look at how fragmented the market is today and some of the big names playing. (GE Healthcare, Siemens, Agfa-Gevaert, Hologic, Pie Medical, AQUILAB, MIM Software, Merge Healtcare, ScienceSoft, Acuo Tech. to name the big players) Most a equipment makers who develop their own software to use witht he equipment, with overlapping functionality for $PME. So that's a big source of $PME's competitive advantage, as its machine-maker agnostic.
Just to be clear, my market size analysis is for SOFTWARE only. Not the hardware. The global hardware market is worth north of A$70bn.
3) My Conclusion
These are just quick, rough calculations you can do in a few minutes. They're broadbrush. They are almost certainly wrong.
BUT, I just have to believe too much to have a conviction that $PME represents a good investment at $228, let alone $248,
There are too many other established players investing to compete for me to believe that $PME will eventually own some 50% of the total addressible market. It's a long bow to draw. Of course, if you are prepared to believe that, then equally, the analysis shows the valuations are justified for the long term. Afterall, maybe they do become the Windows of Medical Imaging! In software, there are precendents, e.g., Google for search.
I would consider investing today in $PME around $120-$150. I'd have to do a deeper dive to find my entry point, but that's a ballpark based on what I've done in 30 minutes. (My CommSec alert is at $170 ... don't think it will triggered any time soon.)
I don't believe today's news of a $300m, 10-year contract warrants a SP movement of +$2bn. These are the kinds of deals $PME MUST bring in, if it is to justify any valuation north of $150. Of course, the SP move could be rational if the market is efficienctly assessing this deal as increasing the chances of success that $PME is going to eventually dominate this market.
So, there you go. Let's see how well this post ages. And above all, do your own research!
Well done to all you have invested in $PME - my hat off to you, and this post shows how analysis can get in the way of being a great investor. But I am going to stick to my process - it serves me well more often than it lets me down.
Reflection
As a personal anecdote, a friend of a StrawPerson at last week's Brisbane drinks had just bought their first ASX shares. $PME at the recommendation of a friend at (I recall) about $217. As I drove home in my Uber after the drinks, I wondered what the conversation would be in a year's time. It didn't cross my mind they'd be up 14% in one week!
Disc: Not held, never have. ;-(